Isotechnika Pharma Inc IPHAF

RE: will nothing save this POS?

[blog]

ISA (T) Cdn$0.84 Stock Rating: Outperform - (Unchanged) Target: Cdn$3.25 - (Unchanged) Risk Rating: Speculative - (Unchanged) Management confirmed its focus on releasing the Phase IIb renal transplant trial results in April. This is the important near-term, value-driving milestone for the company. We believe that a clear safety advantage of ISA247 over the market leader, combined with its ease of dose titration, and strong patent protection, could be the basis for a next generation transplant rejection drug. Management is very committed to doing all the right things to ensure Roche exercises its option and triggers a US$75-million payment to Isotechnika. We highlight this as an excellent buying opportunity. OUTPERFORM, $3.25 target.